FCGR3A and cancer: Studies have shown that cancer patients homozygous for CD16A-158V responded significantly better to tumor targeting mAbs (11–13), indicating that increased binding affinity between CD16A and tumor-targeting mAbs will enhance NK cell anti-tumor effector functions.